Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.Am J Hum Genet. 2003; 72: 1117-1130
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.N Engl J Med. 2017; 377: 523-533
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Ann Oncol. 2019; 30: 558-566
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.N Engl J Med. 2018; 379: 753-763
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.Ann Oncol. 2020; 31: 1526-1535
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med. 2021; 384: 2394-2405
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.Jama. 2017; 318: 825-835
- Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.J Clin Oncol. 2021; 39: 2698-2709
- Replacing Molecular Genetic Testing With Immunohistochemistry Using Antibodies That Recognize the Protein Products of Gene Rearrangements: "Next-generation" Immunohistochemistry.Am J Surg Pathol. 2021; 45: 584-586
- Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases.Am J Surg Pathol. 2002; 26: 413-420
- MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.Hum Pathol. 2014; 45: 2270-2280
- Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study.Am J Surg Pathol. 2020; 44: 214-223
- Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.Mod Pathol. 2020; 33: 1041-1055
- The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.Mod Pathol. 2022; 35: 193-201
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.Proc Natl Acad Sci U S A. 2009; 106: 18740-18744
- MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.J Pathol. 2018; 244: 143-150
- MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.Am J Surg Pathol. 2011; 35: 92-99
- Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.Mod Pathol. 2011; 24: 1169-1176
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.Cancer Cell. 2002; 2: 367-376
- Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.Am J Surg Pathol. 2017; 41: 1547-1551
- Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.Am J Surg Pathol. 2019; 43: 1693-1700
- Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential.Histopathology. 2019; 75: 213-224
- Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.JCO Precis Oncol. 2017; 2017
- IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.Cancer Res. 2016; 76: 7118-7129
- Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.Mod Pathol. 2020; 33: 1056-1064
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.Nat Commun. 2018; 9: 1816
- A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.Clin Breast Cancer. 2019; 19: e589-e592
- Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.Histopathology. 2020; 76: 865-874
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004; 351: 2817-2826
- A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med. 2002; 347: 1999-2009
- Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol. 2009; 27: 1160-1167
- A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.Clin Cancer Res. 2011; 17: 6012-6020
- A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.Clin Cancer Res. 2008; 14: 2601-2608
Gradishar WJ, Moran MS, Abraham J et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 20, 2022, 691-722; Accessed July 2022.
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2016; 34: 1134-1150
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.J Clin Oncol. 2017; 35: 2838-2847
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.J Clin Oncol. 2019; 37: 1956-1964
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.J Clin Oncol. 2022; 40: 1816-1837
- Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.Ann Oncol. 2015; 26: 1533-1546
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.Ann Oncol. 2019; 30: 1541-1557
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Ann Oncol. 2021; 32: 1216-1235
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.CA Cancer J Clin. 2017; 67: 93-99
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.N Engl J Med. 2015; 373: 2005-2014
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.N Engl J Med. 2018; 379: 111-121
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med. 2021; 385: 2336-2347
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.J Clin Oncol. 2010; 28: 1677-1683
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.J Natl Cancer Inst. 2017; 109
- 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.Breast Cancer Res Treat. 2017; 166: 69-76
- Gene expression profiling predicts clinical outcome of breast cancer.Nature. 2002; 415: 530-536
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.N Engl J Med. 2016; 375: 717-729
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.N Engl J Med. 2019; 380: 2395-2405
- Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.J Clin Oncol. 2021; 39: 557-564
- The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Breast Cancer Res Treat. 2017; 165: 65-76
- Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.Ann Surg Oncol. 2018; 25: 3158-3164
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.J Clin Oncol. 2020; 38: 1346-1366
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.J Clin Oncol. 2018; 36: 2105-2122
- Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.Appl Immunohistochem Mol Morphol. 2010; 18: 268-272
- Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.Mod Pathol. 2012; 25: 869-876
- ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.Breast J. 2014; 20: 37-45
- Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.Breast J. 2018; 24: 889-893
- High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.J Clin Oncol. 2011; 29: 4279-4285
- Ki67 in breast cancer: prognostic and predictive potential.Lancet Oncol. 2010; 11: 174-183
- Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst. 2009; 101: 736-750
- Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol. 2011; 22: 1736-1747
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Ann Oncol. 2013; 24: 2206-2223
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.J Natl Cancer Inst. 2021; 113: 808-819
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol. 2020; 38: 3987-3998
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann Oncol. 2021; 32: 1571-1581
- Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol. 2010; 28: 105-113
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol. 2018; 19: 40-50
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol. 2013; 31: 860-867
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.J Clin Oncol. 2019; 37: 559-569
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Ann Oncol. 2015; 26: 259-271
- The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.Ann Oncol. 2021; 32: 1236-1244
- OncoKB: A Precision Oncology Knowledge Base.JCO Precis Oncol. 2017; 2017
- Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies.Stat Med. 2022; 41: 1361-1375
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.Mod Pathol. 2020; 33: 1746-1752
- Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020; 382: 810-821
- Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization.Cancer Cell Int. 2021; 21: 266
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.Sci Transl Med. 2015; 7: 313ra182
- Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.Breast Cancer Res. 2020; 22: 56
- Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer.JNCI Cancer Spectr. 2021; 5
- Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.J Clin Oncol. 2021; 39: 3959-3977
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.J Clin Oncol. 2020; 38: 1887-1896
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med. 2022; 387: 9-20
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Nature. 2018; 554: 189-194
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med. 2019; 380: 1929-1940
- Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Breast Cancer Res. 2020; 22: 45
- A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.Future Oncol. 2022; 18: 2339-2349
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.Lancet Oncol. 2020; 21: 1296-1308
- Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.Nat Commun. 2021; 12: 3770
- Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med. 2013; 368: 1199-1209
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.Ann Oncol. 2018; 29: 145-153
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.Nat Commun. 2018; 9: 896
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.Cancer Discov. 2018; 8: 1390-1403
- Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.Clin Cancer Res. 2018; 24: 5860-5872
- Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.Ann Oncol. 2019; 30: 945-952
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.J Natl Cancer Inst. 2021; 113: 309-317
- Genomic profile of advanced breast cancer in circulating tumour DNA.Nat Commun. 2021; 12: 2423
- Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.JCO Precis Oncol. 2021; 5
- Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Clin Cancer Res. 2022; 28: 1500-1506
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.JAMA Oncol. 2020; 6: 1410-1415
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Ann Oncol. 2021; 32: 229-239
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.JAMA Oncol. 2019; 5: 1473-1478
- Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.JAMA Oncol. 2020; 6: 84-91
Article info
Footnotes
SOURCE OF FUNDING SUPPORT: H. Wen is supported in part by a National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30CA008748).
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
